Skip to main content

Table 1 Characteristics and results of hen’s egg and cow’s milk OIT RCTs

From: Debates in Allergy Medicine: Does oral immunotherapy shorten the duration of milk and egg allergy? The pro argument

Egg Burks et al. (2012) Escudero et al. (2015) Yanagida et al. (2016) Jones et al. (2016)
Study design RCT double blinded RCT, not blinded RCT, not blinded RCT, follow-up
Age range (years) 5–11 (median age: 7 ys) 5–17 (median age: 8 ys) ≥5 5–11 (median age: 7 ys)
Number of patients (active group) 40 30 21 40
Number of patients (control group) 15 31 12 15
Withdrew from therapy (active group) 5 2 5 5
Withdrew from therapy (control group) 2 0 0 2
OIT duration 22 months 3 months 10 weeks 48 months
Maximum tolerated dose 2 g one undercooked egg every 2 days 62–194 mg 2 g
DBPCFC after OIT in placebo group At month 10 (5 g) 100% positive Not performed Not performed Not performed
DBPCFC after OIT in active group At month 10 22 negative (55%) (P < 0.001) At month 22 (10 g) 30 negative (75%) (P < 0.001) Not performed Not performed Not performed
Time of elimination diet (weeks) 4–6 4 2 4–6
DBPCFC after food avoidance (cumulative maximum dose) At month 24 (10 g)
11 negative
At month 4 (3,6 g)
1 negative in CG
11 negative in AG
At week 12 (3 g)
0 negative in CG
7 negative in AG
At month 36
18 negative
At month 48
20 negative
Sustained unresponsiveness (%) 28 (P = 0.03) 37 33,3 (P = 0.032) 45% at year 3
50% at year 4
Milk Yanagida et al. (2015) Wood et al. (2016) Takahashi et al. (2016)
Study design RCT, not blinded RCT, double blinded RCT, not blinded
Age range (years) ≥5 7–35
AG median 11.7 years
CG median 9.5 years
5–17
AG median 9 years
CG median 7 years
Number of patients (active group) 12 28 (OIT plus omalizumab) 31
Number of patients (placebo group) 25 29(OIT plus placebo) 17
Withdrew from therapy (active group) 0 2 0 at year 1
11 at year 4
Withdrew from therapy (placebo group) 0 5 0
OIT duration 12 months 30 months 4 years
Maximum tolerated dose 3 ml 3.8 g 200 ml
DBPCFC after OIT in placebo group 4 negative (3 ml) 20 negative (10 g) 0 negative (80 ml)
DBPCFC after OIT in active group 9 negative (3 ml) 24 negative (10 g) 14 negative (80 ml)
Time of elimination diet (weeks) 2 8 2
DBPCFC after food avoidance (cumulative maximum dose) At month 12.5 (3 ml)
4 negative in CG
7 negative in AG
At month 12.5 (25 ml)
0 negative in CG
4 negative in AG
At month 32 (10 g)
10 negative in CG
13 negative in AG
At year 1 (80 ml)
7 negative/31
At year 2 (80 ml)
14 negative/30
Sustained unresponsiveness (%) 58.3%
P = 0.018
33.3%
P = 0.007
35.7% in CG
48.1% in AG
At year 1 21%
At year 2 47%
P = 0.008